Tlenoterapia hiperbaryczna w leczeniu ostrego zespołu wieńcowego
Appendices
Appendix 1. Search strategies 2004
COCHRANE LIBRARY
#1 MeSH descriptor HYPERBARIC OXYGENATION explode all trees
#2 (hyperbaric near/6 oxygen*)
#3 hbot
#4 high next pressure next oxygen*
#5 MeSH descriptor atmosphere exposure chambers this term only
#6 (monoplace near/6 chamber*)
#7 (multiplace near/6 chamber*)
#8 (atmosphere* near/6 chamber*)
#9 (#1 or #2 or #3 or #4 or #6 or #7 or #8)
#10 MeSH descriptor MYOCARDIAL ISCHEMIA explode all trees
#11 myocardial next infarct*
#12 heart next infarct* 913
#13 cardiac next infarct* 51
#14 coronary next thrombosis 212
#15 acute next coronary 1019
#16 myocardial next ischaemi* 413
#17 myocardial next ischemi* 2217
#18 coronary next disease 6128
#19 (coronary near/6 disease)
#20 heart next disease*
#21 unstable next angina
#22 coronary next arteriosclerosis
#23 coronary
#24 ami
#25 chd
#26 (ischaemic near/6 heart)
#27 (ischaemic near/6 heart)
#28 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)
#29 (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 )
#30 (#28 or #29)
#27 (#30 and #9)
MEDLINE
1 Hyperbaric Oxygenation/
2 Atmosphere Exposure Chambers/
3 hyperbaric oxygen$.tw.
4 high pressure oxygen.tw.
5 hbot.tw.
6 ((monoplace or multiplace) adj5 chamber$).tw.
7 or/1‐6
8 exp Myocardial Ischemia/
9 myocardial infarct$.tw.
10 heart infarct$.tw.
11 coronary thrombosis.tw.
12 acute coronary.tw.
13 myocardial ischaemi$.tw.
14 myocardial ischemi$.tw.
15 heart disease.tw.
16 (coronary adj3 disease).tw.
17 unstable angina.tw.
18 coronary arteriosclerosis.tw.
19 (ischaemic adj3 heart).tw.
20 (ischaemic adj3 heart).tw.
21 ami.tw.
22 chd.tw.
23 or/8‐22
24 7 and 23
25 randomized controlled trial.pt.
26 controlled clinical trial.pt.
27 Randomized controlled trials/
28 random allocation/
29 double blind method/
30 single‐blind method/
31 or/25‐30
32 exp animal/ not humans/
33 31 not 32
34 clinical trial.pt.
35 exp Clinical trials/
36 (clin$ adj25 trial$).ti,ab.
37 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
38 placebos/
39 placebo$.ti,ab.
40 random$.ti,ab.
41 research design/
42 or/34‐41
43 42 not 32
44 43 not 33
45 comparative study.pt.
46 exp evaluation studies/
47 follow up studies/
48 prospective studies/
49 (control$ or prospectiv$ or volunteer$).ti,ab.
50 or/45‐49
51 50 not 32
52 51 not (33 or 44)
53 33 or 44 or 52
54 24 and 53
EMBASE
1 Ischemic Heart Disease/
2 Hyperbaric Oxygen/
3 hyperbaric oxygen$.tw.
4 high pressure oxygen.tw.
5 hbot.tw.
6 ((monoplace or multiplace) adj5 chamber$).tw.
7 or/2‐6
8 exp Ischemic Heart Disease/
9 myocardial infarct$.tw.
10 heart infarct$.tw.
11 coronary thrombosis.tw.
12 acute coronary.tw.
13 myocardial ischaemi$.tw.
14 myocardial ischemi$.tw.
15 heart disease.tw.
16 (coronary adj3 disease).tw.
17 unstable angina.tw.
18 coronary arteriosclerosis.tw.
19 (ischaemic adj3 heart).tw.
20 (ischaemic adj3 heart).tw.
21 ami.tw.
22 chd.tw.
23 or/8‐22
24 7 and 23
25 clinical trial/
26 random$.tw.
27 randomized controlled trial/
28 trial$.tw.
29 follow‐up.tw.
30 double blind procedure/
31 placebo$.tw.
32 placebo/
33 factorial$.ti,ab.
34 (crossover$ or cross‐over$).ti,ab.
35 (double$ adj blind$).ti,ab.
36 (singl$ adj blind$).ti,ab.
37 assign$.ti,ab.
38 allocat$.ti,ab.
39 volunteer$.ti,ab.
40 Crossover Procedure/
41 Single Blind Procedure/
42 or/25‐41
43 exp animal/
44 nonhuman/
45 exp animal experiment/
46 or/43‐45
47 exp human/
48 46 not 47
49 42 not 48
50 24 and 49
CINAHL
1 Hyperbaric Oxygenation/
2 exp Myocardial Ischemia/
3 Hyperbaric Oxygenation/
4 hyperbaric oxygen$.tw.
5 high pressure oxygen.tw.
6 hbot.tw.
7 ((monoplace or multiplace) adj5 chamber$).tw.
8 or/3‐7
9 exp Myocardial Ischemia/
10 myocardial infarct$.tw.
11 heart infarct$.tw.
12 coronary thrombosis.tw.
13 acute coronary.tw.
14 myocardial ischaemi$.tw.
15 myocardial ischemi$.tw.
16 heart disease.tw.
17 (coronary adj3 disease).tw.
18 unstable angina.tw.
19 coronary arteriosclerosis.tw.
20 (ischaemic adj3 heart).tw.
21 (ischaemic adj3 heart).tw.
22 ami.tw.
23 chd.tw.
24 or/9‐23
25 8 and 24
Appendix 2. Search strategies 2007
COCHRANE LIBRARY
#1 MeSH descriptor HYPERBARIC OXYGENATION explode all trees
#2 (hyperbaric near/6 oxygen*)
#3 hbot
#4 high next pressure next oxygen*
#5 MeSH descriptor atmosphere exposure chambers this term only
#6 (monoplace near/6 chamber*)
#7 (multiplace near/6 chamber*)
#8 (atmosphere* near/6 chamber*)
#9 (#1 or #2 or #3 or #4 or #6 or #7 or #8)
#10 MeSH descriptor MYOCARDIAL ISCHEMIA explode all trees
#11 myocardial next infarct*
#12 heart next infarct* 913
#13 cardiac next infarct* 51
#14 coronary next thrombosis 212
#15 acute next coronary 1019
#16 myocardial next ischaemi* 413
#17 myocardial next ischemi* 2217
#18 coronary next disease 6128
#19 (coronary near/6 disease)
#20 heart next disease*
#21 unstable next angina
#22 coronary next arteriosclerosis
#23 coronary
#24 ami
#25 chd
#26 (ischaemic near/6 heart)
#27 (ischaemic near/6 heart)
#28 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)
#29 (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 )
#30 (#28 or #29)
#27 (#30 and #9)
MEDLINE
1 Hyperbaric Oxygenation/
2 Atmosphere Exposure Chambers/
3 hyperbaric oxygen$.tw.
4 high pressure oxygen.tw.
5 hbot.tw.
6 ((monoplace or multiplace) adj5 chamber$).tw.
7 or/1‐6
8 exp Myocardial Ischemia/
9 myocardial infarct$.tw.
10 heart infarct$.tw.
11 coronary thrombosis.tw.
12 acute coronary.tw.
13 myocardial ischaemi$.tw.
14 myocardial ischemi$.tw.
15 heart disease.tw.
16 (coronary adj3 disease).tw.
17 unstable angina.tw.
18 coronary arteriosclerosis.tw.
19 (ischaemic adj3 heart).tw.
20 (ischaemic adj3 heart).tw.
21 ami.tw.
22 chd.tw.
23 or/8‐22
24 7 and 23
25 randomized controlled trial.pt.
26 controlled clinical trial.pt.
27 Randomized controlled trials/
28 random allocation/
29 double blind method/
30 single‐blind method/
31 or/25‐30
32 exp animal/ not humans/
33 31 not 32
34 clinical trial.pt.
35 exp Clinical trials/
36 (clin$ adj25 trial$).ti,ab.
37 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
38 placebos/
39 placebo$.ti,ab.
40 random$.ti,ab.
41 research design/
42 or/34‐41
43 42 not 32
44 43 not 33
45 comparative study.pt.
46 exp evaluation studies/
47 follow up studies/
48 prospective studies/
49 (control$ or prospectiv$ or volunteer$).ti,ab.
50 or/45‐49
51 50 not 32
52 51 not (33 or 44)
53 33 or 44 or 52
54 24 and 53
55 limit 54 to yr="2004 ‐ 2007"
EMBASE
1 Ischemic Heart Disease/
2 Hyperbaric Oxygen/
3 hyperbaric oxygen$.tw.
4 high pressure oxygen.tw.
5 hbot.tw.
6 ((monoplace or multiplace) adj5 chamber$).tw.
7 or/2‐6
8 exp Ischemic Heart Disease/
9 myocardial infarct$.tw.
10 heart infarct$.tw.
11 coronary thrombosis.tw.
12 acute coronary.tw.
13 myocardial ischaemi$.tw.
14 myocardial ischemi$.tw.
15 heart disease.tw.
16 (coronary adj3 disease).tw.
17 unstable angina.tw.
18 coronary arteriosclerosis.tw.
19 (ischaemic adj3 heart).tw.
20 (ischaemic adj3 heart).tw.
21 ami.tw.
22 chd.tw.
23 or/8‐22
24 7 and 23
25 clinical trial/
26 random$.tw.
27 randomized controlled trial/
28 trial$.tw.
29 follow‐up.tw.
30 double blind procedure/
31 placebo$.tw.
32 placebo/
33 factorial$.ti,ab.
34 (crossover$ or cross‐over$).ti,ab.
35 (double$ adj blind$).ti,ab.
36 (singl$ adj blind$).ti,ab.
37 assign$.ti,ab.
38 allocat$.ti,ab.
39 volunteer$.ti,ab.
40 Crossover Procedure/
41 Single Blind Procedure/
42 or/25‐41
43 exp animal/
44 nonhuman/
45 exp animal experiment/
46 or/43‐45
47 exp human/
48 46 not 47
49 42 not 48
50 24 and 49
51 limit 50 to yr="2004 ‐ 2007"
CINAHL
1 Hyperbaric Oxygenation/
2 exp Myocardial Ischemia/
3 Hyperbaric Oxygenation/
4 hyperbaric oxygen$.tw.
5 high pressure oxygen.tw.
6 hbot.tw.
7 ((monoplace or multiplace) adj5 chamber$).tw.
8 or/3‐7
9 exp Myocardial Ischemia/
10 myocardial infarct$.tw.
11 heart infarct$.tw.
12 coronary thrombosis.tw.
13 acute coronary.tw.
14 myocardial ischaemi$.tw.
15 myocardial ischemi$.tw.
16 heart disease.tw.
17 (coronary adj3 disease).tw.
18 unstable angina.tw.
19 coronary arteriosclerosis.tw.
20 (ischaemic adj3 heart).tw.
21 (ischaemic adj3 heart).tw.
22 ami.tw.
23 chd.tw.
24 or/9‐23
25 8 and 24
26 limit 25 to yr="2007 ‐ 2014"
Appendix 3. Search strategies 2010
CENTRAL
#1 MeSH descriptor HYPERBARIC OXYGENATION explode all trees
#2 (hyperbaric near/6 oxygen*)
#3 hbot
#4 high next pressure next oxygen*
#5 MeSH descriptor atmosphere exposure chambers this term only
#6 (monoplace near/6 chamber*)
#7 (multiplace near/6 chamber*)
#8 (atmosphere* near/6 chamber*)
#9 (#1 or #2 or #3 or #4 or #6 or #7 or #8)
#10 MeSH descriptor MYOCARDIAL ISCHEMIA explode all trees
#11 myocardial next infarct*
#12 heart next infarct*
#13 cardiac next infarct*
#14 coronary next thrombosis
#15 acute next coronary
#16 myocardial next ischaemi*
#17 myocardial next ischemi*
#18 coronary next disease
#19 (coronary near/6 disease)
#20 heart next disease*
#21 unstable next angina
#22 coronary next arteriosclerosis
#23 coronary
#24 ami
#25 chd
#26 (ischaemic near/6 heart)
#27 (ischaemic near/6 heart)
#28 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)
#29 (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 )
#30 (#28 or #29)
#27 (#30 and #9)
OVID MEDLINE
1. Hyperbaric Oxygenation/
2. Atmosphere Exposure Chambers/
3. hyperbaric oxygen$.tw.
4. high pressure oxygen.tw.
5. hbot.tw.
6. ((monoplace or multiplace) adj5 chamber$).tw.
7. or/1‐6
8. exp Myocardial Ischemia/
9. myocardial infarct$.tw.
10. heart infarct$.tw.
11. coronary thrombosis.tw.
12. acute coronary.tw.
13. myocardial ischaemi$.tw.
14. myocardial ischemi$.tw.
15. heart disease.tw.
16. (coronary adj3 disease).tw.
17. unstable angina.tw.
18. coronary arteriosclerosis.tw.
19. (ischaemic adj3 heart).tw.
20. (ischaemic adj3 heart).tw.
21. ami.tw.
22. chd.tw.
23. or/8‐22
24. 7 and 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. Randomized controlled trials/
28. Random Allocation/
29. Double‐Blind Method/
30. single‐blind method/
31. or/25‐30
32. exp animal/ not humans/
33. 31 not 32
34. clinical trial.pt.
35. exp Clinical Trials as Topic/
36. (clin$ adj25 trial$).ti,ab.
37. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
38. Placebos/
39. placebo$.ti,ab.
40. random$.ti,ab.
41. Research Design/
42. or/34‐41
43. 42 not 32
44. 43 not 33
45. comparative study.pt.
46. evaluation studies/
47. Follow‐Up Studies/
48. Prospective Studies/
49. (control$ or prospectiv$ or volunteer$).ti,ab.
50. or/45‐49
51. 50 not 32
52. 51 not (33 or 44)
53. 33 or 44 or 52
54. 53 and 24
55. (200909$ or 200910$ or 200911$ or 200912$ or 2010$).ed.
56. 54 and 55
OVID EMBASE
1 Hyperbaric Oxygen/
2 hyperbaric oxygen$.tw.
3 high pressure oxygen.tw.
4 hbot.tw.
5 ((monoplace or multiplace) adj5 chamber$).tw.
6 or/1‐5
7 exp Ischemic Heart Disease/
8 myocardial infarct$.tw.
9 heart infarct$.tw.
10 coronary thrombosis.tw.
11 acute coronary.tw.
12 myocardial ischaemi$.tw.
13 myocardial ischemi$.tw.
14 heart disease.tw.
15 (coronary adj3 disease).tw.
16 unstable angina.tw.
17 coronary arteriosclerosis.tw.
18 (ischaemic adj3 heart).tw.
19 (ischaemic adj3 heart).tw.
20 ami.tw.
21 chd.tw.
22 or/7‐21
23 6 and 22
24 clinical trial/
25 random$.tw.
26 randomized controlled trial/
27 trial$.tw.
28 follow‐up.tw.
29 double blind procedure/
30 placebo$.tw.
31 placebo/
32 factorial$.ti,ab.
33 (crossover$ or cross‐over$).ti,ab.
34 (double$ adj blind$).ti,ab.
35 (singl$ adj blind$).ti,ab.
36 assign$.ti,ab.
37 allocat$.ti,ab.
38 volunteer$.ti,ab.
39 Crossover Procedure/
40 Single Blind Procedure/
41 or/24‐40
42 exp animal/ not exp human/
43 41 not 42
44 23 and 43
45. ("200938" or "200939" or 20094$ or 20095$ or "2010").em.
46. 44 and 45
EBSCO CINAHL
S22 S15 and S21
S21 S16 or S17 or S18 or S19 or S20
S20 EM 200912
S19 EM 200911
S18 EM 200910
S17 EM 200909
S16 EM 2010
S15 S7 and S14
S14 S8 or S9 or S10 or S11 or S12 or S13
S13 monoplace chamber
S12 multiplace chamber
S11 high pressure oxygen
S10 HBOT
S9 hyperbaric oxygen*
S8 MH "Hyperbaric Oxygenation"
S7 S1 or S2 or S3 or S4 or S5 or S6
S6 "heart infarct*"
S5 "unstable angina"
S4 coronary
S3 ami
S2 myocardial
S1 MH "myocardial ischemia+"
Appendix 4. Search strategies 2014
CENTRAL
#1 MeSH descriptor HYPERBARIC OXYGENATION explode all trees
#2 (hyperbaric near/6 oxygen*)
#3 hbot
#4 high next pressure next oxygen*
#5 MeSH descriptor atmosphere exposure chambers this term only
#6 (monoplace near/6 chamber*)
#7 (multiplace near/6 chamber*)
#8 (atmosphere* near/6 chamber*)
#9 (#1 or #2 or #3 or #4 or #6 or #7 or #8)
#10 MeSH descriptor MYOCARDIAL ISCHEMIA explode all trees
#11 myocardial next infarct*
#12 heart next infarct*
#13 cardiac next infarct*
#14 coronary next thrombosis
#15 acute next coronary
#16 myocardial next ischaemi*
#17 myocardial next ischemi*
#18 coronary next disease
#19 (coronary near/6 disease)
#20 heart next disease*
#21 unstable next angina
#22 coronary next arteriosclerosis
#23 coronary
#24 ami
#25 chd
#26 (ischaemic near/6 heart)
#27 (ischaemic near/6 heart)
#28 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)
#29 (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 )
#30 (#28 or #29)
#27 (#30 and #9)
OVID MEDLINE
1. Hyperbaric Oxygenation/
2. Atmosphere Exposure Chambers/
3. hyperbaric oxygen$.tw.
4. high pressure oxygen.tw.
5. hbot.tw.
6. ((monoplace or multiplace) adj5 chamber$).tw.
7. or/1‐6
8. exp Myocardial Ischemia/
9. myocardial infarct$.tw.
10. heart infarct$.tw.
11. coronary thrombosis.tw.
12. acute coronary.tw.
13. myocardial ischaemi$.tw.
14. myocardial ischemi$.tw.
15. heart disease.tw.
16. (coronary adj3 disease).tw.
17. unstable angina.tw.
18. coronary arteriosclerosis.tw.
19. (ischaemic adj3 heart).tw.
20. (ischaemic adj3 heart).tw.
21. ami.tw.
22. chd.tw.
23. or/8‐22
24. 7 and 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. Randomized controlled trials/
28. Random Allocation/
29. Double‐Blind Method/
30. single‐blind method/
31. or/25‐30
32. exp animal/ not humans/
33. 31 not 32
34. clinical trial.pt.
35. exp Clinical Trials as Topic/
36. (clin$ adj25 trial$).ti,ab.
37. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
38. Placebos/
39. placebo$.ti,ab.
40. random$.ti,ab.
41. Research Design/
42. or/34‐41
43. 42 not 32
44. 43 not 33
45. comparative study.pt.
46. evaluation studies/
47. Follow‐Up Studies/
48. Prospective Studies/
49. (control$ or prospectiv$ or volunteer$).ti,ab.
50. or/45‐49
51. 50 not 32
52. 51 not (33 or 44)
53. 33 or 44 or 52
54. 53 and 24
55. (2010$ or 2011$ or 2012$ or 2013$ or 2014$).ed.
56. 54 and 55
OVID EMBASE
1 Hyperbaric Oxygen/
2 hyperbaric oxygen$.tw.
3 high pressure oxygen.tw.
4 hbot.tw.
5 ((monoplace or multiplace) adj5 chamber$).tw.
6 or/1‐5
7 exp Ischemic Heart Disease/
8 myocardial infarct$.tw.
9 heart infarct$.tw.
10 coronary thrombosis.tw.
11 acute coronary.tw.
12 myocardial ischaemi$.tw.
13 myocardial ischemi$.tw.
14 heart disease.tw.
15 (coronary adj3 disease).tw.
16 unstable angina.tw.
17 coronary arteriosclerosis.tw.
18 (ischaemic adj3 heart).tw.
19 (ischaemic adj3 heart).tw.
20 ami.tw.
21 chd.tw.
22 or/7‐21
23 6 and 22
24 clinical trial/
25 random$.tw.
26 randomized controlled trial/
27 trial$.tw.
28 follow‐up.tw.
29 double blind procedure/
30 placebo$.tw.
31 placebo/
32 factorial$.ti,ab.
33 (crossover$ or cross‐over$).ti,ab.
34 (double$ adj blind$).ti,ab.
35 (singl$ adj blind$).ti,ab.
36 assign$.ti,ab.
37 allocat$.ti,ab.
38 volunteer$.ti,ab.
39 Crossover Procedure/
40 Single Blind Procedure/
41 or/24‐40
42 exp animal/ not exp human/
43 41 not 42
44 23 and 43
45. ("2010" or "2011" or "2012" or "2013" or "2014").em.
46. 44 and 45
EBSCO CINAHL
S22 S15 and S21
S21 S16 or S17 or S18 or S19 or S20
S20 EM 200912
S19 EM 200911
S18 EM 200910
S17 EM 200909
S16 EM 2010
S15 S7 and S14
S14 S8 or S9 or S10 or S11 or S12 or S13
S13 monoplace chamber
S12 multiplace chamber
S11 high pressure oxygen
S10 HBOT
S9 hyperbaric oxygen*
S8 MH "Hyperbaric Oxygenation"
S7 S1 or S2 or S3 or S4 or S5 or S6
S6 "heart infarct*"
S5 "unstable angina"
S4 coronary
S3 ami
S2 myocardial
S1 MH "myocardial ischemia+"
Study flow diagram
Forest plot of comparison: 1 Death, outcome: 1.1 Death at any time.
Comparison 1: Death, Outcome 1: Death at any time
Comparison 1: Death, Outcome 2: Death ‐ best case scenario
Comparison 1: Death, Outcome 3: Death ‐ worst case scenario
Comparison 2: Major Adverse Cardiac Events, Outcome 1: Major Adverse Cardiac Events
Comparison 2: Major Adverse Cardiac Events, Outcome 2: MACE ‐ Best case scenario
Comparison 2: Major Adverse Cardiac Events, Outcome 3: MACE ‐ worst case scenario
Comparison 2: Major Adverse Cardiac Events, Outcome 4: Recurrent acute myocardial infarction (AMI)
Comparison 2: Major Adverse Cardiac Events, Outcome 5: Recurrent AMI ‐ best case scenario
Comparison 2: Major Adverse Cardiac Events, Outcome 6: Recurrent AMI ‐ Worst case scenario
Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 1: Overall (CHB, VF and asystole combined)
Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 2: Significant dysrrythmias (complete heart block, ventricular fibrillation or asystole)
Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 3: Overall best case
Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 4: Overall worst case
Comparison 4: Time to pain relief, Outcome 1: Time to relief of pain
Comparison 5: Magnitude of cardiac enzyme changes, Outcome 1: 12 hour Plasma Creatine Phosphokinase
Comparison 5: Magnitude of cardiac enzyme changes, Outcome 2: 24 hour Plasma Creatine Phosphate
Comparison 5: Magnitude of cardiac enzyme changes, Outcome 3: Maximum Plasma Creatine Phosphate
Comparison 6: Improvement in left ventricular function, Outcome 1: Improved contraction in at least one segment (post‐HBOT echo)
Comparison 6: Improvement in left ventricular function, Outcome 2: Left Ventricular Ejection Fraction‐ % (final estimate)
Comparison 7: Length of Stay, Outcome 1: Overall length of stay (days)
Comparison 8: Adverse events of therapy, Outcome 1: Total adverse events
| hyperbaric oxygen therapy for acute coronary syndrome | ||||||
| Patient or population: patients with acute coronary syndrome | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect | No of Participants | Quality of the evidence | Comments | |
|---|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | |||||
| Control | hyperbaric oxygen therapy | |||||
| Death at any time | Study population | RR 0.58 | 614 | ⊕⊕⊝⊝ | ||
| 116 per 1000 | 67 per 1000 | |||||
| Medium risk population | ||||||
| 102 per 1000 | 59 per 1000 | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). | ||||||
| GRADE Working Group grades of evidence | ||||||
| 1 Critical outcome | ||||||
| hyperbaric oxygen therapy for acute coronary syndrome | ||||||
| Patient or population: patients with acute coronary syndrome | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect | No of Participants | Quality of the evidence | Comments | |
|---|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | |||||
| Control | hyperbaric oxygen therapy | |||||
| 12 hour Plasma Creatine Phosphokinase | The mean 12 hour Plasma Creatine Phosphokinase in the intervention groups was | 84 | ⊕⊕⊕⊝ | |||
| 24 hour Plasma Creatine Phosphate | The mean 24 hour Plasma Creatine Phosphate in the intervention groups was | 72 | ⊕⊕⊕⊝ | |||
| Maximum Plasma Creatine Phosphate | The mean Maximum Plasma Creatine Phosphate in the intervention groups was | 184 | ⊕⊕⊕⊕ | |||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). | ||||||
| GRADE Working Group grades of evidence | ||||||
| 1 Single trial only | ||||||
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1.1 Death at any time Show forest plot | 5 | 614 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.58 [0.36, 0.92] |
| 1.1.1 Subjects presenting in cardiogenic shock | 1 | 12 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.61 [0.32, 1.18] |
| 1.1.2 Subjects presenting without cardiogenic shock | 5 | 602 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.57 [0.33, 0.98] |
| 1.2 Death ‐ best case scenario Show forest plot | 5 | 617 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.37 [0.23, 0.58] |
| 1.3 Death ‐ worst case scenario Show forest plot | 5 | 617 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.34 [0.91, 1.96] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 2.1 Major Adverse Cardiac Events Show forest plot | 1 | 61 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.12 [0.02, 0.85] |
| 2.2 MACE ‐ Best case scenario Show forest plot | 1 | 69 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.09 [0.01, 0.61] |
| 2.3 MACE ‐ worst case scenario Show forest plot | 1 | 69 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.56 [0.23, 1.40] |
| 2.4 Recurrent acute myocardial infarction (AMI) Show forest plot | 1 | 129 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.28 [0.08, 0.95] |
| 2.5 Recurrent AMI ‐ best case scenario Show forest plot | 1 | 129 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.17 [0.05, 0.55] |
| 2.6 Recurrent AMI ‐ Worst case scenario Show forest plot | 1 | 129 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.92 [0.42, 2.02] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 3.1 Overall (CHB, VF and asystole combined) Show forest plot | 1 | 208 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.59 [0.39, 0.89] |
| 3.2 Significant dysrrythmias (complete heart block, ventricular fibrillation or asystole) Show forest plot | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 3.2.1 Complete heart block | 1 | 208 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.32 [0.12, 0.84] |
| 3.2.2 Ventricular fibrillation | 1 | 208 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.78 [0.36, 1.71] |
| 3.2.3 Asystole | 1 | 208 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.73 [0.34, 1.56] |
| 3.3 Overall best case Show forest plot | 1 | 221 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.51 [0.34, 0.77] |
| 3.4 Overall worst case Show forest plot | 1 | 221 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.73 [0.50, 1.06] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 4.1 Time to relief of pain Show forest plot | 1 | 81 | Mean Difference (IV, Fixed, 95% CI) | ‐353.00 [‐487.55, ‐218.45] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 5.1 12 hour Plasma Creatine Phosphokinase Show forest plot | 1 | 84 | Mean Difference (IV, Fixed, 95% CI) | ‐138.00 [‐843.83, 567.83] |
| 5.2 24 hour Plasma Creatine Phosphate Show forest plot | 1 | 72 | Mean Difference (IV, Fixed, 95% CI) | ‐65.00 [‐530.96, 400.96] |
| 5.3 Maximum Plasma Creatine Phosphate Show forest plot | 2 | 184 | Mean Difference (IV, Fixed, 95% CI) | ‐493.16 [‐838.74, ‐147.58] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 6.1 Improved contraction in at least one segment (post‐HBOT echo) Show forest plot | 1 | 34 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.09 [0.01, 1.40] |
| 6.2 Left Ventricular Ejection Fraction‐ % (final estimate) Show forest plot | 2 | 190 | Mean Difference (IV, Random, 95% CI) | 5.47 [2.19, 8.75] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 7.1 Overall length of stay (days) Show forest plot | 1 | 64 | Mean Difference (IV, Fixed, 95% CI) | ‐1.80 [‐3.70, 0.10] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 8.1 Total adverse events Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 8.1.1 Tympanic membrane rupture | 2 | 269 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.56 [0.19, 107.54] |
| 8.1.2 Acute neurological oxygen toxicity | 2 | 274 | Risk Ratio (M‐H, Fixed, 95% CI) | Not estimable |
| 8.1.3 Claustrophobia | 1 | 208 | Risk Ratio (M‐H, Fixed, 95% CI) | 31.60 [1.92, 521.22] |
